[ad_1]
The CEO of Acasti Pharma Inc. (NASDAQ: CSTA) (CVE: ACST) talks with Andrew Scott of Proactive after announcing that their second Phase III trial of CaPre drug had achieved 100% randomization – which means that the last patient was accepted into the trial and randomized on the drug or on a placebo.
This milestone means that the company remains on track to release its end results towards the end of the year.
CaPre to treat hypertriglyceridemia (high triglyceride levels in the blood), known to contribute to heart disease.
Source link
